Evidence map›Paper›PMID 36733930›Full record

ArticleBioactive materials2023

Nanofiber matrix formulations for the delivery of Exendin-4 for tendon regeneration:

Sama Abdulmalik, Jack Gallo, Jonathan Nip, Sara Katebifar, Michael Arul, Amir Lebaschi, Lucas N Munch, Jenna M Bartly, Shilpa Choudhary, Ivo Kalajzic and 3 more

Open access · goldAbstract read
In one paragraph

Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sama AbdulmalikDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Jack GalloDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Jonathan NipDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Sara KatebifarDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Michael ArulDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Amir LebaschiDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Lucas N MunchDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Jenna M BartlyDepartment of Immunology, Center on Aging, University of Connecticut Health, Farmington, CT, USA.
Shilpa ChoudharyDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Ivo KalajzicDepartment of Reconstructive Sciences, University of Connecticut Health, Farmington, CT, USA.
Yeshavanth Kumar Banasavadi-SiddegowdaeSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Syam P NukavarapuDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Sangamesh G KumbarDepartment of Orthopedic Surgery, University of Connecticut Health, Farmington, CT, USA.
UConn Health · USUniversity of Connecticut · USNational Institutes of Health · US

Funding

Targeting PHLPP to treat interval disc degeneration using surgical and drug delivery methodsR01AR078908 · NIAMS · EMORY UNIVERSITY · PI Svenja Illien-Junger · 2022 to 2026
$1.9M
Biodegradable Matrices for Bone HealingR01EB020640 · NIBIB · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KUMBAR, SANGAMESH GURAPPA, YU, XIAOJUN · 2017 to 2020
$1.6M
Polysaccharide putty formulations for tissue regenerationR01EB034202 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Sangamesh Gurappa Kumbar · 2023 to 2026
$1.5M
Biodegradable Matrices with Structural and Physical Cues for Interface EngineeringR01EB030060 · NIBIB · UNIVERSITY OF CONNECTICUT STORRS · PI NUKAVARAPU, SYAM · 2020 to 2024
$1.4M
Engineered Matrices with Electrical and Chemical Stimulation for Peripheral Nerve RepairR56NS122753 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KUMBAR, SANGAMESH GURAPPA · 2022 to 2022
$410k
NIAMS NIH HHS R01 AR078908NIBIB NIH HHS R01 EB020640NIBIB NIH HHS R01 EB030060NIBIB NIH HHS R01 EB034202NINDS NIH HHS R56 NS122753
6 · The paper itself

Abstract

Tendon and ligament injuries are the most common musculoskeletal injuries, which not only impact the quality of life but result in a massive economic burden. Surgical interventions for tendon/ligament injuries utilize biological and/or engineered grafts to reconstruct damaged tissue, but these have limitations. Engineered matrices confer superior physicochemical properties over biological grafts but lack desirable bioactivity to promote tissue healing. While incorporating drugs can enhance bioactivity, large matrix surface areas and hydrophobicity can lead to uncontrolled burst release and/or incomplete release due to binding. To overcome these limitations, we evaluated the delivery of a peptide growth factor (exendin-4; Ex-4) using an enhanced nanofiber matrix in a tendon injury model. To overcome drug surface binding due to matrix hydrophobicity of poly(caprolactone) (PCL)-which would be expected to enhance cell-material interactions-we blended PCL and cellulose acetate (CA) and electrospun nanofiber matrices with fiber diameters ranging from 600 to 1000 nm. To avoid burst release and protect the drug, we encapsulated Ex-4 in the open lumen of halloysite nanotubes (HNTs), sealed the HNT tube endings with a polymer blend, and mixed Ex-4-loaded HNTs into the polymer mixture before electrospinning. This reduced burst release from ∼75% to ∼40%, but did not alter matrix morphology, fiber diameter, or tensile properties. We evaluated the bioactivity of the Ex-4 nanofiber formulation by culturing human mesenchymal stem cells (hMSCs) on matrix surfaces for 21 days and measuring tenogenic differentiation, compared with nanofiber matrices in basal media alone. Strikingly, we observed that Ex-4 nanofiber matrices accelerated the hMSC proliferation rate and elevated levels of sulfated glycosaminoglycan, tendon-related genes (Scx, Mkx, and Tnmd), and ECM-related genes (Col-I, Col-III, and Dcn), compared to control. We then assessed the safety and efficacy of Ex-4 nanofiber matrices in a full-thickness rat Achilles tendon defect with histology, marker expression, functional walking track analysis, and mechanical testing. Our analysis confirmed that Ex-4 nanofiber matrices enhanced tendon healing and reduced fibrocartilage formation versus nanofiber matrices alone. These findings implicate Ex-4 as a potentially valuable tool for tendon tissue engineering.

Indexed as

Halloysite nanotubesNanofiber matrix formulationProtein deliverySoft tissue regeneration

Identifiers

PMID36733930
PMCPMC9876843
OpenAlexW4317598164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.